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  Abstract 
    Objectives  . This trial was performed to test the efﬁ  cacy and safety of an extended-release formulation of methylphenidate 
(MPH ER).   Methods  . A total of 162 adults with ADHD according to DSM-IV were treated for 8 weeks with either two 
daily individually body weight-adjusted doses of MPH ER up to 1 mg/kg per day (  N        84) or placebo (  N        78). The 
primary efﬁ  cacy outcome was the Wender  –  Reimherr Adult Attention Deﬁ  cit Disorder Scale (WRAADDS) 8 weeks after 
randomization. Secondary efﬁ  cacy measures were the ADHD Diagnostic Checklist (ADHD-DC), the Conners Adult 
Attention Deﬁ  cit Disorder Scale (CAARS-S:L), the Clinical Global Impression (CGI) and the Sheehan Disability Scale 
(SDS).   Results  . At week 8 a signiﬁ  cantly higher decline of the total WRAADDS score was found in the MPH ER group 
as compared to the placebo group (  P        0.0003). The rates of responders were 50% in the MPH ER and 18% in the 
placebo group (  P        0.0001). Furthermore, similar effects were observed for the secondary efﬁ  cacy variable: ADHD-DC 
score (  P        0.004), CAARS-S:L score (  P        0.008) and the SDS score (  P        0.017). 50% of the MPH ER group and 
24.4% of the placebo group were improved   “  much  ”   or   “  very much  ”   according to the CGI rating (  P        0.0001). MPH 
ER treatment was well tolerated. At week 2 also the mean heart rate was signiﬁ  cantly higher in the MPH ER group as 
compared to the placebo group (  P        0.01). No differences between the study groups were observed regarding mean 
blood pressure at any visit.   Conclusions  . This clinical trial demonstrated statistically signiﬁ  cant and clinical relevant effects 
of MPH ER in adults with ADHD for several self- and investigator-rated ADHD psychopathology and also functional 
efﬁ  cacy measures.   
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    Introduction 
  Attention-deﬁ   cit/hyperactivity disorder (ADHD) is 
one of the most common psychiatric conditions in 
childhood, with approximately 6  –  9% of school-age 
children being affected (Barkley and Murphy 1998). 
Studies have found that up to 60  –  65% of affected 
children continue to suffer from this disease as adults, 
with it becoming a chronic condition in approxi-
mately 3.4% adult people worldwide (Fayyad et al. 
2007). Considering the prevalence of adult ADHD 
and the negative impact its symptoms may have on 
the different domains of a patient’    s life (Goodman 
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trials have also considered treatment effects on addi-
tional symptom domains which are related to ADHD 
in adult patients like disorganization and problems 
with emotional regulation. Decline of different 
measures of emotional dysregulation, oppositional 
symptoms and disorganization in adults with ADHD 
have been shown as a result of methylphenidate 
treatment in several randomized placebo-controlled 
trials (Reimherr et al. 2007; R  ö  sler et al. 2009, 
2010b; Marchant et al. 2010). Also improvement of 
self concept and action control has been observed 
under methylphenidate treatment in adults with 
ADHD (Edel et al. 2009). Moreover, positive effects 
of stimulants on a functional level and measures of 
quality of life have been reported (Spencer et al. 
2008). Likewise, a signiﬁ  cant effect of methylpheni-
date on social adjustment over a period of one 
year could be demonstrated (Wender et al. 2010). 
Thus, there is much evidence from a large number 
of independent studies that stimulant medications 
and methylphenidate in particular have a beneﬁ  cial 
effect on ADHD core and associated symptoms, and 
also on every day functioning. 
  The purpose of this study was to test the hypoth-
eses that treatment with an extended release formu-
lation of methylphenidate (MPH ER) not only 
reduces (1) the core symptom domains of ADHD, 
inattention, hyperactivity and impulsiveness, but also 
(2) the broader psychopathological spectrum of 
adult ADHD according to the Utah criteria, which 
comprise symptoms of emotional dysregulation and 
disorganization, and (3) may improve every day 
functioning in adults with ADHD. In this study we 
used a twice a day dosing schedule with a sustained 
release MPH preparation instead of a single dose in 
the morning in order to adapt treatment effects to 
the needs of adult ADHD patients. Moreover, this 
study was the ﬁ   rst in adults with ADHD that 
employed individually body-weight adjusted daily 
MPH ER doses for an optimal balance of efﬁ  cacy 
and side effects.     
  Methods 
  Subjects were outpatients with ADHD aged 18 years 
and older. For study inclusion the subject had to 
fulﬁ  l the DSM-IV criteria for ADHD (314.00 and 
314.01). The diagnosis was established by clinical 
assessment and by use of a German standardized 
diagnostic instrument for psychiatric experts 
(ADHD-DC, R  ö  sler et al. 2004). A retrospective 
assessment of DSM-IV ADHD symptoms was made 
in the presence of an informant whenever possible. 
In addition, the German short version of the Wender 
Utah Rating scale (WURS, Wender 1995) was 
administered to all subjects in order to make sure 
2007), it should be recognized as an important men-
tal disorder requiring accurate identiﬁ  cation  and 
treatment (R  ö  sler et al. 2010a). 
  The longest-used medications for ADHD are stim-
ulants which have been used in the management of 
childhood ADHD since the 1930s (Bradley 1937). 
Methylphenidate was ﬁ   rst synthesized 1944, and 
introduced into therapeutics in 1954. Beginning in 
the 1960s, it was used to treat children with ADHD. 
Until the 2000s, options in terms of stimulants were 
limited to immediate-release (IR) and ﬁ  rst-generation 
extended-release (ER) formulations (Stein 2004). 
Now, a number of extended-release stimulant medi-
cations are available in European and non-European 
countries (R  ö  sler et al. 2010a). 
  Based on their favorable efﬁ  cacy proﬁ  les, stimu-
lants have become the standard medical treatment for 
ADHD in children and adults and are recommended 
as ﬁ  rst line pharmacological treatment as one com-
ponent of multimodal therapy by several evidence-
based guidelines (Ebert et al. 2003; Nutt et al. 2007; 
NICE 2008). Stimulants have been proved effective 
in the treatment of ADHD in all ages. A growing 
number of clinical studies has given substantial evi-
dence that MPH treatment is efﬁ  cacious and safe also 
in adult ADHD patients. In several meta-analyses 
moderate to high standardized effect sizes (Cohen’    s 
  d    ’  ) on the reduction of ADHD core symptoms were 
calculated from studies of appropriate design and 
methodological standards. In a ﬁ  rst  meta-analysis, 
Faraone et al. (2004) included six trials with meth-
ylphenidate in adult ADHD. They found a mean 
effect size of   d    ’        0.9 and no evidence of publication 
bias. Larger MPH effect sizes were associated with 
physician ratings of outcome and use of higher doses. 
More recently, an overall effect size of   d    ’      0.42 was 
reported from a meta-analysis of 16 studies with 
methylphenidate in adult ADHD patients (Koesters 
et al. 2009). Regression analysis showed no signiﬁ  -
cant inﬂ  uence of mean daily dose on effect size and 
no publication bias. Efﬁ   cacy of pharmacological 
treatment of 1991 adults with ADHD from 11 stim-
ulant and non-stimulant treatment trials has been 
analyzed in a third meta-analytical approach by 
M  é  sz  á  ros et al. (2009). The effect size for stimu-
lants was   d    ’        0.67 and somewhat higher than for 
non-stimulant medications, where an effect size of 
  d    ’        0.59 was calculated from the data. Similarly, in 
a meta-analysis of 19 treatment studies a signiﬁ  cant 
higher effect size was found for stimulants (  d    ’        0.73 
and 0.86 for long-acting and short-acting stimulants, 
respectively) than for non-stimulants (  d    ’        0.39) 
(Faraone and Glatt 2010). 
  Beside the reduction of ADHD symptoms accord-
ing to DSM-IV, which focus on inattention, hyper-
activity and impulsivity, recent pharmacological 50     W. Retz et al.     
with a block size of 4. The block size was not men-
tioned in the investigational plan or the consent 
given to patients. 
  MPH ER is a MPH preparation manufactured by 
Medice Company (Germany) with a proportion of 
50% immediate release MPH and 50% of extended 
release MPH. The effective time of action is 7  –  8 h 
(Garcia-Garcia et al. 2009). The effects of a single 
dose of this drug are comparable to the effects of 
twice daily immediate release MPH. The drug is 
available in several European countries and has been 
approved for the treatment of children and adoles-
cents with ADHD up to age 18 years. Its dosing 
proﬁ   le predicts a larger immediate and smaller 
delayed action than OROS MPH, with individual 
differences in time course being observed. The drug 
was described and compared with other long acting 
MPH medications by the European guideline group 
(Banaschewski et al. 2006). 
  Medication was individually titrated b.i.d. after 
breakfast and lunch during the ﬁ  rst 2 weeks to an 
optimal dose on the basis of tolerability and accord-
ing to the body weight with a maximum daily dose 
of approximately 1 mg/kg body weight, starting 
with 10  –  30 mg/day. Patients were assigned to one 
of four weight classes (less than 55 kg, 55  –  69 kg, 
70  –  104 kg and 105  –  130 kg) with doses of 40, 
60, 80 and 120 mg daily, respectively. The interval 
between the two doses was 6  –  8 h. A standardised 
disease management programme consisting of 
seven sessions was administered individually to all 
participants of the study. The programme has 
already been used in an earlier study (R  ö  sler et al. 
2009) and was implemented in this study as a man-
datory part of the treatment according to advice of 
the German authorities, to improve compliance 
and to avoid inconsistencies regarding information 
about and coping with ADHD within the study 
population. Disease management sessions were 
performed at baseline and six visits up to week 8. 
During these sessions patients received information 
about ADHD aetiology and symptoms, support in 
perception of symptoms and speciﬁ  c problems, help 
with the management of self-regulation and emo-
tional problems, time management and performing 
daily routines.     
  Assessments 
  Each subject underwent a comprehensive clinical 
assessment by a certiﬁ  ed psychiatrist using stan-
dardized rating scales and interviews. The clinical 
examination included medical history, physical and 
neurological examination, assessments of vital para-
meters, body weight, liver function tests, complete 
blood count, ECG and EEG. 
that childhood ADHD symptoms were present by a 
retrospective self report of the patient. A cut-off 
score of at least 30 points served as an indicator 
of apparent childhood ADHD psychopathology 
(Retz-Junginger et al. 2002, 2003). Subjects with 
WURS-k scores     30 were not included. 
  Before inclusion of a subject in the study, each 
case has been re-evaluated by a central control com-
mittee of experienced psychiatrists (MR, WR) for 
veriﬁ   cation of patient eligibility. Anamnestic data, 
standardized ADHD ratings and diagnostic inter-
views (WRAADDS, SKID-I/-II), were cross-checked 
for any inconstancies in order to make the diagnoses 
of ADHD as sure as possible. Inclusion and exclu-
sion criteria were carefully re-examined to avoid 
protocol violations. 
  The German versions of the SCID-I and   –  II 
interviews (SKID-I and   –  II, Wittchen et al. 1997) 
were used to assess comorbid psychiatric diagnoses. 
Individuals with low intelligence (IQ      85), demen-
tia, schizophrenia, bipolar disorder, current major 
depression, acute anxiety disorders and other unsta-
ble psychiatric conditions were excluded, as were 
subjects with any serious medical illness. Also sub-
jects with drug or alcohol dependence during the 
6 months before screening, pregnant or nursing 
women, persons with a Body Mass Index     20 or 
body weight     130 kg, and individuals treated with 
any psychopharmacological drug in addition to 
study medication were not included. Urine screen-
ings for drugs of abuse were performed at screening 
visit and at week 8 and could be repeated at any 
time of the study at the investigator  ’  s discretion. A 
wash-out period of at least 2 weeks was necessary 
for any psychopharmacological drug before study 
inclusion. 
  The study was approved by the ethical committee 
of the State of the Saarland and has been performed 
in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki. The trial has 
been registered with the Federal Opium Agency at 
the Federal Institute for Drugs and Medical Devices 
as well as at ClinicalTrials.gov (NCT00730249). 
Subjects were included in the study after provided 
written informed consent.   
  Procedure 
  A double-blind, randomized, placebo-controlled 
study with parallel-group design was conducted at 
10 sites. The treatment period was 8 weeks with a 
2-week titration and a 6-week maintenance phase. 
  Randomisation was performed by Medice’s 
Galenic Department which included the generation 
of the randomisation list and the preparation of 
emergency envelopes. We used block randomisation      Clinical trial with methylphenidate in adult ADHD            51
rating scale contains 40 items referring to 10 neuro-
logical and 30 somatic symptoms.     
  Statistical analyses 
  The total score of the WRAADDS after 8 weeks was 
analysed as primary variable. The total score is the 
sum of all items (in case of missing items the sum 
was divided by the number of items answered and 
multiplied by 28). Missing data were imputed using 
the last-observation carried forward (LOCF) proce-
dure (only one measurement was missing). 
  The primary analysis was performed on the intent-
to-treat (ITT) population using a linear mixed effects 
model with ﬁ  xed effect treatment, covariate baseline 
WRAADDS and random effect centre. We applied a 
signiﬁ  cance level of   α        0.05 (two-sided) for the 
primary conﬁ  rmatory test (  F  -test of the ﬁ  xed effect). 
Additional sensitivity analyses were performed to 
test the robustness of the primary analyses with 
regard to the imputed data (under a best- and a 
worst-case scenario). All secondary endpoints were 
analysed exploratively either with the Wilcoxon 
  U-  test (at least ordinal scale) or with Fisher  ’  s exact 
test (binary data). 
  A sample size of 64 in each treatment group has 
80% power to detect a difference in means of 7 assum-
ing that the common standard deviation is 14 under 
a two-group   t  -test scenario with a signiﬁ  cance level 
  α   of 5% (two-sided). Since a dropout rate of about 
15% was expected, a total of 75 patients should be 
recruited for each of the two treatment groups.       
  Results 
  A total of 162 patients were randomized and 
included in this trial. 84 patients received MPH 
ER and 78 placebo during the double-blind study 
period (Figure 1). Seven subjects discontinued the 
study prematurely, four in the placebo group and 
three in the MPH ER group. Reasons for prema-
ture discontinuation were adverse events in three 
patients of the MPH ER group and one of the 
placebo group. One patient in the MPH ER group 
discontinued due to lack of efﬁ  cacy. In the placebo 
group one drop-out was related to the need of 
antihypertensive medication, another withdrew 
the consent. 
  Prior to randomization, i.e. at the beginning of 
the treatment phase, we also compared both groups 
descriptively. There was no evidence for difference 
in mean age, ADHD symptom score by ADHD-DC 
and WRAADDS score, CGI severity ratings, SDS 
score and IQ between the MPH ER and the placebo 
group at the beginning of the treatment phase. 
  The primary outcome measure was the total score 
of the Wender-Reimherr Adult Attention Deﬁ  cit Dis-
order Scale (WRAADDS, Wender 1995, Rösler et al. 
2010c). The WRAADDS has been validated in 
German populations by R  ö  sler et al. (2008a,b). This 
structured interview consists of 28 items in seven 
psychopathological domains, which are rated by a 
clinical expert on a 0  –  2 Likert scale. The psycho-
pathological domains are inattention, hyperactivity, 
affective lability, hot temper, stress intolerance, dis-
organization and impulsivity. The raters were required 
to attend training with observed interviews to stan-
dardize rating practices for this instrument before the 
study started. WRAADDS assessments were per-
formed at screening and at the end of the double-
blind maintenance phase (week 8). Subjects were 
required to have a WRAADDS score of more than 
35 points at screening to be included into the study. 
  Assessments of the ADHD DSM-IV criteria at 
screening and at week 8 were performed by use of 
the German version of the ADHD Rating Scale-IV 
(ADHD RS-IV, DuPaul et al. 1998), which is the 
ADHD-DC (R  ö  sler et al. 2004). This expert rating 
refers to the nine psychopathological DSM-IV crite-
ria for inattentiveness and the nine criteria for hyper-
activity and impulsivity. Each item is rated by an 
expert as present (1) or not present (0), resulting in 
a maximum score of 26. 
  The 66-item long version of the CAARS self 
report scale (CAARS-S:L, Conners et al. 1999) was 
used as a second outcome measure. This instrument 
comprises the 18 DSM-IV items of ADHD psycho-
pathology. The CAARS-S:L was administered at 
screening and at week 8. An inconsistency index     7 
at baseline lead to exclusion from the study. 
  Overall severity, change of severity, improvement, 
overall therapeutic effects and tolerability were 
assessed with the Clinical Global Impression scale 
(CGI, NIMH 1985). CGI ratings were performed at 
screening and at week 8. 
  The Sheehan Disability Scale (SDS) was used for 
the assessment of the degree to which ADHD inter-
feres in function regarding three domains of daily liv-
ing: work/school, social and family life. The extent of 
impairment in these domains was rated by the patient 
on a 0  –  10 point visual analogue scale. The three items 
were summed up to a single measure of global func-
tional impairment that ranges from 0 to 30 (Sheehan 
1983, Sheehan and Sheehan 2008). SDS scores were 
assessed at screening and at week 8. 
  Adverse events were assessed at each visit. Patients 
were asked for any complaints and new adverse 
symptoms. In addition, standardized assessments of 
adverse events were performed at weeks 1, 2 and 8 
by use of the somatic symptom sheet of the AMDP-
system (AMDP 2006; Guy and Ban 1982). This 52     W. Retz et al.     
  At week 8 the mean daily doses at week 8 were 66      
20 mg in the MPH ER group (males 80.0      8.8 mg, 
females 66.9      15.8 mg) and 78      17 mg in 
the placebo group (Wilcoxon   U  -test,   P        0.0001). 
These  are equivalent to 0.9      0.2 mg/kg body 
weight MPH ER and 0.9      0.1 mg/kg body weight 
placebo, respectively (Wilcoxon   U  -test,   P        0.2091). 
Note that there were slightly more women in the 
MPH-ER group and as women weigh on average 
less than men this resulted in a lower average 
daily dose in milligrams in the MPH ER group. In 
addition, dose reductions were descriptively more 
frequent in the MPH-ER than in the placebo group 
Some evidence for differences was found regarding 
sex and body weight/BMI with a preponderance of 
women and subjects with lower body weight/BMI in 
the MPH ER group (Table I). The mean CAARS-
S:L score was also higher in the MPH ER group 
than in the placebo group at the beginning of the 
treatment phase. The incidence of comorbid condi-
tions according to SKID-I interviews is shown in 
Table II. No evidence for difference was observed 
for the proportion of individuals who had received 
earlier MPH treatment (29.8% in the MPH ER 
group and 37.2% in the placebo group; Fisher  ’  s 
exact test,   P        0.32). 
MPH ER
N=84
Placebo
N=78
Premature
Termination
N=4
Premature
Termination
N=3
Randomised
N=162
Completed 
Study
N=80
Completed 
Study
N=75
Screened
N=201
    Figure 1.         Flow diagram of subject progress.   
    Table I. Demographic and clinical characteristics of the intent-to-treat study population at screening. Data are presented as N (%) or 
mean      SD.   
MPH ER 
  N        84
Placebo 
  N        78
Statistics 
  P   values
Age (years) 36.6      10.4 38.2      9.9 Wilcoxon   U  -test 
  P        0.42
Sex
Male
Female
32 (38%)
52 (61%)
44 (56%)
34 (44%)
Fisher  ’  s exact test 
  P        0.0272
Body weight (kg)
Male
Female
73.8      13.7
80.7      11.2
69.6      13.4
82.9      17.1
89.2      17.1
74.7      13.5
Wilcoxon   U  -test 
  P        0.0005
IQ 112.2      13.4 113.3      14.3 Wilcoxon   U  -test 
  P        0.67
ADHD-DC score
Inattention
Hyperactivity/Impulsivity
7.8      1.0
7.1      1.1
7.6      1.0
7.1      1.0
Wilcoxon   U  -test 
  P        0.24 
  P        0.99
WRAADDS score 46.3      5.0 45.4      5.3 Wilcoxon   U  -test 
  P        0.3471
CAARS-S:L score 126.1      31.7 114.4      30.4 Wilcoxon   U  -test 
  P        0.0230
CGI Severity of illness score 5.2      0.7 5.2      0.7 Wilcoxon   U  -test 
  P        0.81
SDS score 19.7      4.7 19.0      5.5 Wilcoxon   U  -test 
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placebo group at week 8 was statistically signiﬁ  cant 
(ITT population, conﬁ  rmatory analysis, mixed linear 
model,   P        0.0003). The results were conﬁ  rmed by 
robustness analyses with worst- and best-case impu-
tations (  P        0.0002 and   P        0.0011, respectively) 
and also by analysis of the per protocol (PP) popula-
tion, which consisted of 143 patients who completed 
the study without any major protocol violations 
(mixed linear model,   P        0.0003). The effect size in 
this analysis was   d    ’        0.59. 
  Explorative analyses of the WRAADDS subscales 
revealed substantial differences at week 8 between 
patients of the MPH ER and the placebo group 
with the exception of the subscales hot temper and 
emotional over-reactivity. The highest effect size 
of   d    ’        0.68 was found regarding attention difﬁ  -
culties (Wilcoxon   U  -test,   P        0.00004). Marked 
effects were also found regarding hyperactivity 
(19 vs. 2 patients). There was no evidence for group 
differences regarding compliance (96% in the MPH 
ER group and 97% in the placebo group).   
  Efﬁ  cacy 
  There was a marked decline of 13.8 points on the 
WRAADDS in the MPH ER group as compared to 
6.2 points in the placebo group during the 8 week 
double-blind treatment period (Figure 2). At week 
8, the WRAADDS score was 32.5 (95% conﬁ  dence 
interval (CI) 29.7  –  35.3) in the MPH ER group and 
39.2 (95% CI 36.6  –  41.8) in the placebo group. The 
mean difference between MPH ER and placebo was 
6.8 points (95% CI 3.2  –  10.4) which can be trans-
lated into a standardized effect size of 0.54 in units 
of pooled standard deviations (Cohen’    s   d    ’  ). The 
difference between the MPH ER group and the 
    Table II. Probable and conﬁ  rmed DSM-IV axis-1 and axis-II diagnoses according to SCID-I and -II interviews of the intent-to-treat 
study population (  N  ).   
MPH ER,   N        84 Placebo,   N        78
  DSM-IV Axis-I  lifetime/current lifetime/current
Bipolar disorders 0/0 0/0
Major depression 16/0 15/0
Depression NOS 4/0 3/1
Dysthymia 0/2 0/3
Affective disorder caused by speciﬁ  c factor 0/0 1/0
Substance-induced depressive disorder 0/0 0/0
Psychotic disorders 0/0 0/0
Alcohol abuse/dependence 3/0 9/0
Drug abuse/dependence  ∗  7/0 11/0
Panic disorder 1/0 2/0
Phobic disorders  ∗  17/7 12/5
Generalized anxiety disorder 1/0 1/0
Anxiety disorder caused by speciﬁ  c factor 0/0 0/0
Substance-induced anxiety disorder 0/0 0/0
Anxiety disorder NOS 1/1 0/0
Obsessive-compulsive disorder 4/2 3/0
PTSD 0/0 2/0
Somatization disorder/hypochondriasis  ∗  n.a./2 n.a./4
Body dysmorphic disorder n.a./1 n.a./0
Eating disorders  ∗  5/0 7/1
Adjustment disorders n.a./1 n.a./0
Others 3/1 3/0
  DSM-IV Axis-II 
Avoidant 20 11
Dependent  6  5
Obsessive-compulsive 30 29
Negativistic 18 12
Depressive 12 11
Paranoid 13  7
Schizotypic  1  2
Schizoid  4  2
Histrionic  1  3
Narcissistic  6  9
Borderline 16 14
Antisocial  8  7
Personality disorder NOS  0  0
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hyperactivity/impulsivity (  d    ’        0.58, Wilcoxon 
  U  -test,   P        0.0009). 
  In the MPH ER group the decrease of the CAARS-
S:L total score was 41.5 points over the 8-week 
treatment period. In the placebo group the decline 
was 13.1 points (Figure 3). Note that the placebo 
group showed a slightly higher mean CAARS-S:L 
score as compared to the MPH ER group at the 
beginning of treatment (Wilcoxon   U  -test,   P        0.023). 
However, we observed evidence for a difference 
between patients treated with MPH and those treated 
with placebo at week 8 for the secondary outcome 
CAARS-S:L total score (  d    ’        0.44; Wilcoxon   U  -test, 
  P        0.008). 
  Finally, we also observed evidence for a difference 
regarding functional improvement on the SDS at 
week 8 between the MPH ER and the placebo group 
(Wilcoxon  U  -test,  P       0.0167). The total score decline 
was 6.9 points in the MPH ER group and 3.1 points 
in the placebo group (Figure 4;   d    ’        0.40). 
  The Spearman correlation coefﬁ  cient  between 
the total scores of self and investigator ratings in 
the entire patient group at week 8 were 0.72 for 
ADHD-DC and CAARS-S:L and 0.76 for 
WRAADDS and CAARS-S:L (both   P        0.0001). 
The Spearman correlation coefﬁ  cients between the 
expert ratings ADHD-DC and WRAADDS was 
0.81 (  P        0.0001). Regarding the SDS total score, 
Spearman correlation coefﬁ   cients were 0.67 for 
the correlation with the WRAADDS total score, 
0.57 for the correlation with the ADHD-DC 
total score, and 0.72 for the correlation with the 
CAARS-S:L total score (all   P        0.0001).     
  Responder analyses 
  The number of responders according to the criterion 
of a 30% reduction of the WRAADDS total score at 
study endpoint was 50% for the MPH ER group and 
and impulsivity (Wilcoxon   U  -test,   P        0.00129 and 
  P        0.00447, respectively), which refer together 
with attention difﬁ  culties to the core symptoms of 
ADHD according to the concept of DSM-IV. The 
effect sizes were   d    ’        0.51 and   d    ’        0.46, respec-
tively. Evidence for effects were also found regard-
ing disorganisation (  d    ’        0.42; Wilcoxon   U  -test, 
  P        0.00715) and affective lability (  d    ’        0.31; 
Wilcoxon   U  -test,   P        0.04698). 
  Similar differences were found for other second-
ary measures: At week 8, patients on the placebo 
and the MPH ER group also differed regarding 
ADHD-DC symptom scores (  d    ’        0.54; Wilcoxon 
  U  -test,   P        0.004). The decline on the ADHD-
DC was 5.6 points in the MPH ER group and 
2.6 points in the placebo group. Differences 
between placebo and MPH ER patients at week 8 
were found for both symptom domains   –   inatten-
tion (  d    ’        0.49; Wilcoxon   U  -test,   P        0.009) and 
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    Figure 2.         Mean reduction of the WRAADDS total score at 
week 8 by treatment group (ITT population, Wilcoxon   U  -test, 
  P        0.0003).   
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    Figure 3.         Mean reduction of the CAARRS-S:L total score at 
week 8 by treatment group (ITT population, Wilcoxon   U  -test, 
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adverse events were recorded at the end of the 
titration phase at week 2.     
  Vital signs 
  There was a small but clinically not meaningful 
increase of mean systolic and diastolic blood pres-
sure during the treatment period in both treatment 
groups (Table IV). No signiﬁ  cant differences were 
seen between the treatment groups at any visit. The 
mean heart rate in the MPH ER group showed an 
increase compared to placebo at week 2 (  P        0.01). 
The difference compared to placebo was 4 bpm. At 
week 8 there was still some descriptive evidence for 
18% for the placebo group (Figure 5; Fisher’    s exact 
test,   P        0.0001). 
  Moreover, the improvement assessed by expert 
clinical global impression (CGI) also indicated 
between-group differences. 50% of the MPH ER 
patients and 24.3% of the placebo group showed 
  “  very much  ”   or   “  much  ”   improvement at week 8 
(Wilcoxon   U  -test,   P        0.0001). Marked and mod-
erate therapeutic effects were seen in 50% of the 
patients treated with MPH and in 24.4% of those 
treated with placebo (Wilcoxon   U  -test,   P        0.0001). 
  Because of the inhomogeneous sex distribution 
between the MPH ER and placebo group, the anal-
yses of the primary and secondary outcomes were 
additionally stratiﬁ  ed by sex. Overall, the results for 
WRAADDS, CAARS-S:L, CGI, ADHD-CL and 
the Sheehan Scale all favoured the general claims for 
MPH ER in subgroups of males and females.     
  Adverse events 
  In the double-blind treatment phase 151 adverse 
events were reported in 55 patients of the MPH ER 
group, and 77 in 32 patients of the placebo group 
(Fisher’    s Exact Test,   P        0.003). 63% of all adverse 
events were rated as   “  moderate  ”  . One serious 
adverse event was observed in the MPH ER group 
(rupture of the acromioclavicular joint), and two 
were reported in one patient of the placebo group 
(appendicitis and postoperative pain). The relation 
between SAEs and study medication were rated as 
  “  unlikely  ”   or   “  not related  ”  . 
  Reduced appetite, dry mouth and increased thirst 
were the most frequent side effects assessed with 
the AMDP adverse events list. These side effects 
were more frequently reported for the MPH ER 
group as compared to the placebo group (Table III). 
Backache, excessive appetite and seborrhoea were 
more frequently reported under placebo. Most 
    Table III. Adverse events measured by somatic symptom scale 
of AMDP. Only those adverse events are listed, which were 
signiﬁ  cantly more frequent in either treatment group.   
  MPH ER      Placebo 
  Max. difference 
at week 
  MPH ER 
(%) 
  Placebo 
(%) 
Decreased appetite W2 48 10
Dry mouth W2 38 14
Excessive thirst W2 32 9
Headache W1 30 17
Palpitations W8 25 6
Dizziness W2 23 9
Gastric discomfort W2 17 5
Nausea W1 17 4
  Placebo      MPH ER 
  Placebo 
(%) 
  MPH ER 
(%) 
Backache W1 24 10
Excessive appetite W8 19 4
Drowsiness W2 19 8
Seborrhoea W2  8 1
    Table IV. Week by week pulse (bpm), systolic and diastolic blood 
pressure (BP) values.   P   values are given for treatment group 
differences.   
MPH ER Placebo
Wilcoxon 
  U  -test 
P   values
Screening Systolic BP
Diastolic BP
Pulse
121      11
79      8
71      10
124      11
81      6
71      9
0.08
0.51
0.80
Baseline Systolic BP
Diastolic BP
Pulse
121      13
79      9
73      11
124      11
81      7
75      9
0.14
0.16
0.17
Week 1 Systolic BP
Diastolic BP
Pulse
123      12
80      9
78      11
126      14
81      9
74      10
0.12
0.61
0.08
Week 2 Systolic BP
Diastolic BP
Pulse
124      11
81      10
78      11
125      12
81      10
74      10
0.58
0.86
0.01
Week 8 Systolic BP
Diastolic BP
Pulse
123      12
80      9
76      11
125      12
83      8
73      11
0.61
0.14
0.08
60
50
40
30
20
10
0
P
e
r
c
e
n
t
 
%
MPH ER
Placebo
Responder
    Figure 5.         Responders according to reduction of the WRAADDS 
total score by 30% in the MPH ER and the placebo group.   56     W. Retz et al.     
analysis of the study population without violations of 
the study protocol (per protocol population). 
  It is another important ﬁ  nding of this study that 
MPH treatment has not only a beneﬁ  cial effect on 
ADHD symptoms from the expert  ’  s view, but also 
from the patients themselves. We found a decline of 
the mean CAARS-S:L total score of about one third 
in the MPH group during the 8 weeks of treatment. 
This adds additional support to the clinical relevance 
of the results of this study. In this context it is nota-
ble that also the global clinical situation, rated with 
the CGI and also functional disabilities regarding 
work/school, social and family life, which have 
assessed with the SDS, were improved by MPH 
treatment. We found moderate to high correlations 
between ADHD self and expert ratings and func-
tional impairment assessed with the SDS, which 
might suggest that social problems and ADHD are 
no independent phenomena. Above all, the ﬁ  nding 
of functional improvement together with clinical 
symptoms of ADHD underlines the clinical relevance 
of MPH ER treatment effects found in this study. 
Thus, our results are in line with other recent studies 
regarding the efﬁ  cacy of stimulants in adult ADHD, 
which showed improvement of executive functions, 
quality of life and social adjustment (Spencer et al. 
2008; Weiss et al. 2010; Wender et al. 2010). Taken 
together, there is converging evidence from this and 
other studies that MPH improves psychopathological 
and functional problems in ADHD patients. 
  The effect sizes (Cohen  ’  s   d    ’  ) found in this study 
ranged between 0.31 regarding amelioration of affec-
tive lability and 0.68 regarding the improvement of 
attention difﬁ  culties. The effect size on the primary 
outcome measure, the WRAADDS total score was 
0.54 in the intent-to-treat and 0.59 in the per pro-
tocol population, respectively. The effect size on the 
primary outcome measure in this study compares to 
those seen in earlier MPH studies in adult ADHD 
and exceeds those found in large efﬁ  cacy studies, 
e.g., of antidepressants in affective disorders (Bech 
et al. 2000). The effect sizes, which have been cal-
culated from ratings with several instruments, are in 
the range of those from recent meta-analyses of 
pharmacological treatment in adult ADHD. They 
are somewhat lower than those reported by Faraone 
et al. (2004, 2009) and M  é  sz  á  ros et al. (2009) for 
stimulants (0.67  –  0.9), but higher than the mean 
effect size of 0.42, which has been reported by 
Koesters et al. (2009). In an earlier study with MPH 
ER and a study design very similar to the recent 
study, an effect size of   d    ’        0.39 on the WRAADDS 
as the primary efﬁ  cacy parameter was found (R  ö  sler 
et al. 2009). In this previous clinical trial much lower 
doses of MPH ER and no individual body weight 
adjusted titration of study medication were used. 
a difference between the MPH ER and the placebo 
group (76 vs. 73 bpm;   P        0.08).       
  Conclusions 
  In this randomized clinical trial statistically and 
clinically relevant effects of MPH ER in adult 
patients with ADHD were found in comparison to 
placebo. Differences between patients treated with 
MPH ER and placebo for 8 weeks were observed 
for both the primary and the secondary outcomes, 
i.e. regarding standardized measures of expert 
ratings (WRAADDS, ADHD-DC) as well as on the 
patients  ’   self-reports (CAARS-S:L) of ADHD 
symptoms, the global clinical situation (CGI) and 
everyday functioning (SDS). Thus, the results of 
this study provide evidence for improvement of 
psychopathology and functional impairment asso-
ciated with ADHD from the therapists  ’   and the 
patients  ’   perspective, respectively. 
  The ﬁ  ndings of this study also suggest that MPH 
ER treatment results not only in relevant ameliora-
tion of ADHD core symptoms, which comprise 
symptoms of inattention, hyperactivity and impulsiv-
ity according to DSM-IV, but also of ADHD accord-
ing to the Utah-criteria for adult ADHD. This 
concept has been introduced by P.H. Wender (1995) 
prior to the introduction of the attention disorders 
by DSM-III (1980) and goes beyond DSM-IV. It 
comprises a broader psychopathological spectrum 
and includes the domains disorganization, problems 
with temper control, affective lability and emotional 
over-reactivity beside the classical triade of inatten-
tion, hyperactivity and impulsivity. It is now widely 
accepted that emotional dysregulation and disorga-
nization in daily activities are present as associated 
symptoms in the majority of adult cases with ADHD 
(Gibbins and Weiss 2007). The high correlation 
between the WRAADDS and ADHD-DC ratings, 
which refer to the Utah- and DSM-IV criteria 
respectively, found in this study indicates that both 
concepts are closely related and that, therefore, emo-
tional dysregulation and disorganization might pres-
ent intrinsic ADHD psychopathology. 
  The WRAADDS has been used in several clinical 
trials with adults with ADHD (Michelson et al. 2003; 
Reimherr et al. 2005, 2007; Marchant et al. 2010). 
The results from this study conﬁ  rm  ﬁ  ndings  from 
other clinical trials that suggest amelioration of 
ADHD  core and related symptoms by MPH 
(Reimherr et al. 2007; Marchant et al. 2010; R  ö  sler 
et al. 2010b), particularly of disorganization and 
affective lability. The treatment effect of MPH ER on 
the primary outcome WRAADDS total score proved 
to be robust as statistical signiﬁ  cance was conﬁ  rmed 
by worst- and best-case imputations and also by      Clinical trial with methylphenidate in adult ADHD            57
to minimize inconsistencies within the study popu-
lation. Thus, it cannot be excluded that some thera-
peutic effects observed in this trial might be due 
to this additional non-pharmacological interven-
tion. However, as all patients of the MPH ER 
and the placebo group were provided with the same 
program and the placebo responder rate was similar 
or lower than in other recent trials in adults with 
ADHD (Biederman et al. 2006; R  ö  sler et al. 2009), 
no major non-pharmacological treatment effect can 
be assumed. 
  In conclusion this study showed both statistically 
signiﬁ  cant and clinically relevant improvements in 
ADHD symptoms based on several expert ratings 
and self-report instruments. Further, treatment 
with MPH ER was associated with a decline of 
ADHD symptoms according to DSM-IV as well 
as according to the broader concept of the Utah 
criteria. Importantly, also functional impairment of 
patients was improved after 8 weeks of treatment 
with MPH ER. Treatment with body weight adjusted 
mean daily MPH ER doses of 0.9 mg/kg was well 
tolerated and no severe adverse events related to 
study medication were observed during the study. 
Although no clinical relevant changes of vital signs 
were observed after 8 weeks of treatment, some small 
drug effects on the heart rate during the titration 
phase were observed. Therefore, controls of vital 
signs have to be recommended in the treatment of 
adults with MPH.                             
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The mean MPH ER dose in that earlier study was 
0.55 mg/kg body weight and 0.9 mg/kg body weight 
in the present study. Thus, it might be concluded 
that the therapeutic effect of MPH ER depends on 
the daily dose and that higher doses are associated 
with higher efﬁ  cacy. 
  Although the mean daily doses used in this study 
were not far from the recommended upper dose limit 
of 1.0 mg/kg body weight per day, treatment with 
MPH ER was well tolerated and the observed side 
effects like reduced appetite and dry mouth resem-
bled those reported from other clinical studies. 
Moreover, most side effects were observed during 
the titration phase and were moderate and short-
lasting. In contrast to prior short-term investigations 
with long-acting MPH formulations (Biederman et al. 
2006; Reimherr et al. 2007), we found no signiﬁ  cant 
effect on blood pressure in this study. A slight mean 
elevation of the heart rate was observed during titra-
tion in the MPH ER treatment when compared to 
the placebo group. As a consequence, monitoring of 
vital signs has to be recommended when adults are 
treated with MPH ER. 
  Some limitations of this study have to be men-
tioned. The ﬁ  rst point refers to the diagnostic pro-
cess in ADHD patients, as diagnosing ADHD 
correctly is a crucial issue in any study with adults 
suffering from this disorder. In this study we used 
standardized instruments for the diagnostic proce-
dure, which were applied by well trained psychia-
trists. Moreover, each case has been re-evaluated 
by a central control committee before randomiza-
tion of the subject. Nevertheless, it might be a 
limitation that   –   in contrast to ADHD studies with 
children and adolescents   –   assessments of ADHD 
symptoms and diagnoses were mainly based on 
self-reports of the subjects. In particular, also 
assessment of childhood ADHD symptoms did not 
necessarily rely on third person observations in this 
study. However, diagnostic interviews which were 
primarily used in this study are the fundamental 
basis of every diagnostic process in adult psychia-
try and it has been shown that adults present com-
petent sources of information and that self-reports 
may lead to valid diagnoses in subjects with ADHD 
in particular (Murphy and Schachar 2000; R  ö  sler 
et al. 2006). 
  Another limitation of this study might be the 
implementation of a basic disease management 
program with psychoeducational elements. This 
program was already used in a further study (R  ö  sler 
et al. 2009) according to advices of the German 
authorities. As knowledge about ADHD and the 
competences of coping with ADHD symptoms are 
very variable across adults with ADHD, we decided 
to run this basic psychosocial intervention in order 58     W. Retz et al.     
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